Fortress Biotech, Inc.: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Nov 14, 2024 and accepted by EDGAR at Nov 14, 2024, 16:40 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $14.6m | us-gaap:Revenues |
| Revenue | 9 months2024-01-01 to 2024-09-30 | $42.6m | us-gaap:Revenues |
| Cost of revenue | 3 months2024-07-01 to 2024-09-30 | $5.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2024-01-01 to 2024-09-30 | $18.6m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2024-07-01 to 2024-09-30 | $9.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-01-01 to 2024-09-30 | $46.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-07-01 to 2024-09-30 | $22.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-01-01 to 2024-09-30 | $60.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | −$22.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-30 | −$86.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-07-01 to 2024-09-30 | $69.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-01-01 to 2024-09-30 | −$24.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | −$12.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | −$39.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | −$0.76 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-01-01 to 2024-09-30 | −$2.43 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | −$0.76 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | −$2.43 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 19,697,290 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-01-01 to 2024-09-30 | 19,041,590 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | −$67.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-01-01 to 2024-09-30 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2024-01-01 to 2024-09-30 | $528.0k | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2024-09-30 | $58.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $86.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $127.1m | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $70.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $139.8m | us-gaap:Liabilities |
| Long-term debt | At period end2024-09-30 | $52.5m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2024-09-30 | $21.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-24-015740. Last ingested by Listed: Oct 29, 2026, 17:38 ET. Listed shows no prices and gives no investment advice.